Utah Retirement Systems Mirati Therapeutics, Inc. Transaction History

Utah Retirement Systems

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $5,950 - $8,670	100 Added 1.32%	7,700 $538,000
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $66,005 - $95,145	500 Added 7.04%	7,600 $1.12 Million
Q3 2021 Nov 16, 2021	SELL	$132.13 - $177.45 $39,639 - $53,235	-300 Reduced 4.05%	7,100 $1.26 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $216,000 - $269,595	1,500 Added 25.42%	7,400 $1.2 Million
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $937,627 - $1.31 Million	5,900 New	5,900 $1.01 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Utah Retirement Systems, based on Form 13F filings with the SEC.

Stay updated on Utah Retirement Systems with notifications on news.